You are here: Industry Insights > Novo Nordisk

News List

FDA refuses Novo Nordisk’s once-weekly semaglutide pharmatimes
March 25, 2021
Novo Nordisk has received a refusal to file letter from the US Food and Drug Administration (FDA) for a label expansion application for semaglutide.
Adults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial prnasia
March 24, 2021
New results from the STEP phase 3a clinical trial programme demonstrated weight loss with investigational treatment of once-weekly subcutaneous semaglutide 2.4 mg versus placebo.
Gilead, Novo Nordisk expand NASH clinical collaboration expresspharma
March 19, 2021
Gilead Sciences and Novo Nordisk announced that the companies have expanded their clinical collaboration in non-alcoholic steatohepatitis (NASH).
Novo Nordisk invests in facility expansion at production site in Denmark pharmatimes
February 26, 2021
Novo Nordisk will invest DKK 500 million (£57.96m) to expand facilities at an existing production site in Måløv, Denmark.
Novo Nordisk’s semaglutide cuts body weight in large-scale trial pharmatimes
February 24, 2021
Novo Nordisk’s glucagon-like peptide-1 (GLP-1) agonist semaglutide significantly cut body weight in a large-scale trial of adults who are overweight or obese.
Novo Nordisk’s Sogroya moves closer towards EU approval pharmatimes
February 02, 2021
Novo Nordisk’s Sogroya (somapacitan) has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use – moving closer towards approval in the EU.
Novo Nordisk eyes EU approval for once-weekly semaglutide pharmatimes
December 21, 2020
Danish pharma company Novo Nordisk has submitted a marketing authorisation application the European Medicines Agency (EMA), seeking approval for once-weekly semaglutide for weight management.
Gilead and Novo Nordisk’s NASH trial meets primary endpoint pharmatimes
November 18, 2020
Gilead and Novo Nordisk have announced that a phase II proof-of-concept trial evaluating combination treatments for non-alcoholic steatohepatitis (NASH) met its primary endpoint.
Novo Nordisk to Acquire Emisphere Technologies contractpharma
November 16, 2020
Novo Nordisk entered into a definitive agreement to acquire Emisphere Technologies Inc., a drug delivery company, for $1.35 billion.
Novo Nordisk set to acquire Emisphere for $1.8 billion europeanpharmaceuticalreview
November 13, 2020
Following approval by Emisphere shareholders, Novo Nordisk will acquire the company for a total of $1.8 billion.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 13 14 Next page